company background image
IMRX

Immuneering NasdaqGM:IMRX Stock Report

Last Price

US$4.45

Market Cap

US$117.5m

7D

2.5%

1Y

-55.5%

Updated

29 Jan, 2023

Data

Company Financials +

Immuneering Corporation

NasdaqGM:IMRX Stock Report

Mkt Cap: US$117.5m

IMRX Stock Overview

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.

IMRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Immuneering Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immuneering
Historical stock prices
Current Share PriceUS$4.45
52 Week HighUS$16.17
52 Week LowUS$3.74
Beta0
1 Month Change-8.25%
3 Month Change-67.87%
1 Year Change-55.50%
3 Year Changen/a
5 Year Changen/a
Change since IPO-74.70%

Recent News & Updates

Recent updates

Shareholder Returns

IMRXUS BiotechsUS Market
7D2.5%0.8%2.8%
1Y-55.5%7.1%-9.2%

Return vs Industry: IMRX underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: IMRX underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is IMRX's price volatile compared to industry and market?
IMRX volatility
IMRX Average Weekly Movement12.7%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: IMRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IMRX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200874Ben Zeskindhttps://immuneering.com

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs.

Immuneering Corporation Fundamentals Summary

How do Immuneering's earnings and revenue compare to its market cap?
IMRX fundamental statistics
Market CapUS$117.50m
Earnings (TTM)-US$48.05m
Revenue (TTM)US$506.09k

232.2x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMRX income statement (TTM)
RevenueUS$506.09k
Cost of RevenueUS$364.34k
Gross ProfitUS$141.75k
Other ExpensesUS$48.19m
Earnings-US$48.05m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.82
Gross Margin28.01%
Net Profit Margin-9,494.86%
Debt/Equity Ratio0%

How did IMRX perform over the long term?

See historical performance and comparison